← Evidence map

ArticleAntibody therapeutics2026

Unique loop-structured CD19/CD22 bispecific CAR-T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma: an observational study.

Shuhong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Unique loop-structured CD19/CD22 bispecific CAR-T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma: an observational study. | OpenQuestion